MARKET

ARVN

ARVN

Arvinas
NASDAQ
6.29
-0.23
-3.53%
After Hours: 6.29 0 0.00% 19:20 05/13 EDT
OPEN
6.52
PREV CLOSE
6.52
HIGH
6.62
LOW
6.15
VOLUME
3.10M
TURNOVER
--
52 WEEK HIGH
37.38
52 WEEK LOW
5.94
MARKET CAP
459.12M
P/E (TTM)
-9.5448
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0505-0509)?
Weekly Report · 1d ago
Arvinas Is Maintained at Neutral by Citigroup
Dow Jones · 05/05 21:27
Arvinas Price Target Cut to $9.50/Share From $10.00 by Citigroup
Dow Jones · 05/05 21:27
Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $9.5
Benzinga · 05/05 21:18
Where Arvinas Stands With Analysts
Benzinga · 05/05 21:01
Arvinas Cut to Hold From Buy by Truist Securities
Dow Jones · 05/05 16:17
Arvinas Price Target Cut to $11.00/Share From $21.00 by Truist Securities
Dow Jones · 05/05 16:17
Truist Securities Downgrades Arvinas to Hold, Lowers Price Target to $11
Benzinga · 05/05 16:06
More
About ARVN
More
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Recently
Symbol
Price
%Change

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.